Author:
Vyshedskiy Andrey,Netson Rebecca,Fridberg Elisabeth,Jagadeesan Priyanka,Arnold Matthew,Barnett Sophie,Gondalia Anjali,Maslova Victoria,deTorres Lauren,Ostrovsky Simone,Durakovic Danijel,Savchenko Andrei,McNett Sienna,Kogan Mikhail,Piryatinsky Irene,Gold Dov
Abstract
AbstractLongitudinal cognitive testing is essential for developing novel preventive interventions for dementia and Alzheimer’s disease; however, the few available tools have significant practice effect and depend on an external evaluator. We developed a self-administered 10-minute at-home test intended for longitudinal cognitive monitoring, Boston Cognitive Assessment or BOCA. The goal of this project was to validate BOCA. BOCA uses randomly selected non-repeating tasks to minimize practice effects. BOCA evaluates eight cognitive domains: 1) Memory/Immediate Recall, 2) Language Comprehension/Prefrontal Synthesis, 3) Visuospatial Reasoning / Mental rotation, 4) Executive function / Clock Test, 5) Attention, 6) Mental math, 7) Orientation, and 8) Memory/Delayed Recall. BOCA was administered to patients with cognitive impairment (n = 50) and age- and education-matched controls (n = 50). Test scores were significantly different between patients and controls (p < 0.001) suggesting good discriminative ability. The Cronbach’s alpha was 0.87 implying good internal consistency. BOCA demonstrated strong correlation with Montreal Cognitive Assessment (MOCA) (R= 0.90, p <0.001). The study revealed strong (R=0.94, p <0.001) test-retest reliability of the total BOCA score one week after participants’ initial administration. The practice effect tested by daily BOCA administration over 10 days was insignificant (β=0.03, p=0.74). BOCA has the potential to reduce the cost and improve the quality of longitudinal cognitive tracking essential for testing novel interventions designed to reduce or reverse cognitive aging. BOCA is available online gratis at www.bocatest.org.
Publisher
Cold Spring Harbor Laboratory
Reference20 articles.
1. Obstructive sleep apnea syndrome: an emerging risk factor for dementia;CNS Neurol. Disord.-Drug Targets Former. Curr. Drug Targets-CNS Neurol. Disord,2016
2. Bakulski, K. M. et al. Heavy Metals Exposure and Alzheimer’s Disease and Related Dementias. J. Alzheimers Dis. 1–28 (2020).
3. A comparison of gender-linked population cancer risks between alcohol and tobacco: how many cigarettes are there in a bottle of wine?
4. Tracking cognitive decline in amnestic mild cognitive impairment and early-stage Alzheimer dementia: mini-mental state examination versus neuropsychological battery;Dement. Geriatr. Cogn. Disord,2017
5. Roadmap for interventions preventing cognitive aging;Front. Aging Neurosci,2019